Therapeutic potential of targeting LAG-3 in cancer

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune checkpoint inhibitors targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have improved survival in various solid tumors.
• Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor found on exhausted T cells, playing a role in regulating anti-tumor immunity.

Purpose of the Study:

• To review the current understanding of LAG-3's role in anti-tumor immunity.
• To summarize the clinical development status of LAG-3-directed agents in cancer therapy.

Main Methods:

• Literature review of preclinical and clinical studies on LAG-3.
• Analysis of clinical trial data for LAG-3 inhibitors in various cancer types.

Main Results:

• Dual blockade of LAG-3 and PD-1 with relatlimab and nivolumab demonstrated improved progression-free survival (PFS) in advanced melanoma, leading to FDA approval.
• Despite some negative trial outcomes, novel LAG-3-directed therapies, such as bispecific antibodies, continue to show potential.

Conclusions:

• LAG-3 is a significant target for immuno-oncology, with dual blockade showing clinical benefit in specific cancers.
• Ongoing research and novel therapeutic strategies are crucial for maximizing the potential of LAG-3 inhibition in cancer treatment.